Preview: Bio-Rad Laboratories's Earnings
Portfolio Pulse from Benzinga Insights
Bio-Rad Laboratories (NYSE:BIO) is anticipated to release its quarterly earnings report on February 15, 2024, with an expected EPS of $2.82. Investors are keen on not just the earnings beat but also the forward guidance. The company's past earnings performance shows a mix of beats and misses, with significant price changes following the announcements. Currently, BIO shares are trading at $316.1, marking a 28.78% decline over the last year, indicating investor concern ahead of the earnings release.
February 14, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bio-Rad Laboratories is expected to report an EPS of $2.82 for the upcoming quarter. Past earnings have shown volatility in stock price post-announcement. Shares have declined 28.78% over the last year, reflecting investor sentiment.
Given Bio-Rad Laboratories' mixed past earnings performance and the significant stock price decline over the past year, the upcoming earnings report is crucial. However, the impact of the earnings report on the stock price is uncertain, as it will heavily depend on whether the company meets or exceeds the EPS estimate and provides positive future guidance. The historical data suggests that the company's stock is sensitive to earnings announcements, but investor sentiment and market conditions at the time of the release will also play critical roles.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100